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Abstract CD20 has proven to be an excellent target for the
treatment of B-cell lymphoma, first for the chimeric mon-
oclonal antibody rituximab (Rituxan™), and more recent-
ly for the radiolabelled antibodies Y-90 ibritumomab tiux-
etan (Zevalin™) and I-131 tositumomab (Bexxar™).
Radiation therapy effects are due to beta emissions with
path lengths of 1–5 mm; gamma radiation emitted by I-131
is the only radiation safety issue for either product. Dose-
limiting toxicity for both radiolabelled antibodies is
reversible bone marrow suppression. They produce
response rates of 70%–90% in low-grade and follicular
lymphoma and 40%–50% in transformed low-grade or
intermediate-grade lymphomas. Both products produce
higher response rates than related unlabelled antibodies,
and both are highly active in patients who are relatively
resistant to rituximab-based therapy. Median duration of
response to a single course of treatment is about 1 year
with complete remission rates that last 2 years or longer in
about 25% of patients. Clinical trials suggest that anti-
CD20 radioimmunotherapy is superior to total body irradi-
ation in patients undergoing stem cell supported therapy
for B-cell lymphoma, and that it is a safe and efficacious
modality when used as consolidation therapy following
chemotherapy. Among cytotoxic treatment options, current
evidence suggests that one course of anti-CD20 radioim-
munotherapy is as efficacious as six to eight cycles of
combination chemotherapy. A major question that persists
is how effective these agents are in the setting of ritux-
imab-refractory lymphoma. These products have been
underutilised because of the complexity of treatment coor-
dination and concerns regarding reimbursement.
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CD20 has proven to be an excellent target for the treatment
of B-cell lymphoma [1]. More than 90% of B-cell lym-
phoma cells express CD20, but it is not expressed on cells
in stem cell and progenitor pools. Rituximab (Rituxan,
Genentech Inc., South San Francisco, CA, and Biogen-
IDEC Pharmaceutical Corp, San Diego, CA), a mouse-
human chimeric monoclonal antibody that reacts with
CD20, has proven to be highly effective and relatively
non-toxic in the treatment of B-cell malignancies [2, 3]. As
a single agent in indolent B-cell lymphoma, rituximab pro-
duces response rates ranging from 50% to 80%, with medi-
an response durations of a year or more [4–8]. In combi-
nation with chemotherapy it has produced response rates
of more than 90% [9–11]. Randomised trials have con-
firmed the superiority of giving rituximab concurrently
with chemotherapy in the treatment of large B-cell lym-
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Fax: +1-949-760-2102phoma and low-grade lymphoma [12–16]. Since the intro-
duction of rituximab, survival rates for lymphoma patients
in the general population have improved significantly for
the first time in 30 years [17–19]. However, it is becoming
evident that even rituximab is seldom if ever curative
whether used alone or in combination with chemotherapy,
in low-grade lymphomas. Thus, there is a continuing need
for additional agents in the treatment of low-grade lym-
phomas, whose natural history typically involves a series
of responses to treatment and relapses over a median of
10–15 years, and sometimes for more than 20 years, as
well as in the treatment of more aggressive lymphomas.
During the past 5 years, two additional anti-CD mono-
clonal antibody products have been approved in the United
States for the treatment of B-cell lymphomas: the radiola-
belled antibodies Y-90 ibritumomab tiuxetan (Zevalin™,
Biogen-IDEC Pharmaceuticals, San Diego, CA) and I-131
tositumomab (Bexxar™, GlaxoSmithKline, Research
Triangle Park, NC) [20, 21]. Zevalin was approved for clin-
ical use in February 2002, and Bexxar in June 2003. The
descriptive features of these products are summarised in
Table 1. Rather than modifying the original mouse anti-
bodies ibritumomab and tositumomab to chimeric or
humanised constructs, both were kept as murine proteins in
order to decrease half-life in the circulation, to reduce non-
specific total body irradiation (TBI). Ibritumomab is the
same antibody that was modified to create the chimeric
antibody rituximab; therefore, it has exactly the same bind-
ing to CD20 as rituximab. In addition to possible immuno-
logic or regulatory effects mediated via CD20, both prod-
ucts also produce cytotoxic effects from beta radiation
associated with the decay of their respective isotopes.
Because the path length for the beta radiation extends only
for a few millimetres, there are virtually no radiation safe-
ty issues for that aspect of the therapy. However, the
gamma radiation from I-131 does travel through tissues for
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several feet. In the past, nuclear medicine specialists had
become facile in the use of I-131 for the treatment of
hyperthyroidism and thyroid cancer, but such treatments
historically had been carried out on inpatient units with iso-
lation precautions. In 1998, changes in regulatory standards
by the United States Nuclear Regulatory Commission made
outpatient treatment with I-131 and I-131-labelled antibod-
ies feasible [22, 23]. However, there are still certain radia-
tion safety and relative isolation procedures that are in
place during the administration of the I-131-labelled prod-
uct, including relative isolation from family members for
two to four days, for patients receiving this isotope [24].
The rationale for radioimmunotherapy using monoclon-
al antibodies conjugated to radioisotopes is several-fold.
First, lymphoma cells are typically radiosensitive; so, focal
external beam, total nodal irradiation and TBI have been
used in various treatment strategies for decades. However,
focal external beam radiation requires anatomic localisa-
tion of a target via scans, and TBI dosing is limited by tox-
icity to normal tissue. Radioimmunotherapy is a systemic
therapy that does not require visualisation of the tumour,
and is specific in its targeting of tumour cells; so higher
radiation doses can be delivered to tumour cells than is pos-
sible in TBI approaches with external beam equipment.
Because of radiation path lengths of a few millimetres,
radiolabelled antibodies do not have to bind to every single
tumour cell for a therapeutic effect. This has been called
“the cross-fire effect”. In contrast, unlabelled antibodies
that target tumour surface antigens have no basis for a ther-
apeutic effect in the absence of binding to the tumour cell.
Finally, in radioimmunotherapy the radiolabelled antibod-
ies provide an added dimension, cytotoxic irradiation, to
immunologic and regulatory effects associated with anti-
body binding to antigen/receptor surface molecules.
The schedule for administration of these products is
similar, as illustrated in Fig. 1. Both treatment schemes
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Table 1 Characteristics of anti-CD20 radiolabelled monoclonal antibodies for radioimmunotherapy of CD20-positive B-cell lymphomas
Product Y-90 ibritumomab tiuxetan I-131 tositumomab
Radiolabelled MoAb Mouse anti-CD20 Mouse anti-CD20
Isotope conjugation Indirect: Y-90 chelated to tiuxetan  Direct: I-131 iodination of tyrosine 
which is covalently linked to  amino acids in the antibody
antibody via arginine & lysine 
amino acids
Therapeutic isotope Yttrium-90 Iodine-131
Half-life 2.6 days 8 days
Emission path length and energy 5 mmβ, 2.29 mEv 1 mm β, 0.616 mEv and γ, 0.36 mEv
Unlabelled MoAb given prior  Chimeric rituximab 250 mg/m2 Mouse tositumomab 450 mg
to radiolabelled MoAb
Tracer imaging dose 5 mCi In-111 ibritumomab tiuxetan  5 mCi I-131 tositumomab day 1
day 1
Purpose of tracer/imaging dose Imaging of biodistribution as  Determine retention and urinary clearance 
additional safety measure to calculate therapeutic doseinclude administration of about 500 mg of unlabelled anti-
body to clear CD20-expressing B cells from the circula-
tion and to bind B lymphocytes that reside in the spleen.
This results in a better biodistribution of the relatively
small amount (about 35 mg) of radiolabelled antibody, and
therefore a better opportunity to bind to CD20 on tumour
cells. At the present time both schedules include an imag-
ing dose prior to the treatment dose. In the case of the
yttrium product, this has been required by the US Food
and Drug Administration (FDA) to ensure a relatively nor-
mal biodistribution that includes elimination from the
blood pool, uptake in liver and spleen, but little or no
uptake in the kidneys. For this purpose, indium-111 rather
than yttrium-90 is conjugated to the antibody, via the same
chelating linker, because the latter does not have emissions
that are useful for imaging. At the time of approval the
FDA required two to three scans for the Zevalin treatment
[25], but recently this has been reduced to one, and in
Europe the product has been approved without the require-
ment for such scans as they do not predict efficacy or tox-
icity at the standard dose of 4 mCi/kg up to a maximum
dose of 32 mCi [26–28]. An analysis based on the pre-
treatment weight of patients found no difference in
response rates for those with weights above 80 kg com-
pared to those with weights below 80 mg [29]. The tiuxe-
tan chelator is tightly bound to the antibody, and retains
the yttrium; therefore, clearance of unbound yttrium is not
a significant issue in dosimetric variation. In contrast, in
the case of the iodinated product, the scanning is an essen-
tial part of determining the retention and clearance of the
isotope in order to calculate an optimal therapeutic dose,
inasmuch as 50%–90% of the iodine is cleared in the urine
during the first 48 h after administration, and varies
tremendously from patient to patient. This necessitates
determination of residence time and clearance of the iso-
tope in each individual patient to avoid underdosing or
overdosing the therapeutic dose for an individual patient.
Because of the potential for uptake of radioactive iodine in
the thyroid, free iodine is administered before, during and
after therapy for a total of 4 weeks.
Table 2 summarises the phase I trials that were conduct-
ed with these products. These studies defined maximum tol-
erated doses as 75 cGy of TBI for the I-131 product [30] and
4 mCi/kg for the Y-90 product [31]. The only significant
toxicities observed were mild infusion-associated reactions
related to the binding of the unlabelled antibodies to circu-
lating tumour cells [32], and reversible cytopenias due to
irradiation of haematopoietic precursor cells. The nadir of
the cytopenias typically occurred in the second month after
treatment, and usually returned to normal levels during the
third month. The tumour response rates of around 70% were
much higher than typically reported for phase I trials. About
75% of the patients had indolent or low-grade lymphomas,
in which the response rate was about 80%, and the other
25% had more aggressive histologies in which the response
rate was closer to 40%.
Table 3 summarises the activity of the anti-CD20 radio-
labelled antibodies in patients with low-grade lymphoma
that had relapsed after prior therapy, typically chemothera-
py rather than rituximab, or combinations of chemotherapy
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Table 2 Phase I clinical trials with anti-CD20 radiolabelled monoclonal antibodies for relapsed and transformed indolent B-cell lymphoma
[30, 31]
I-131 tositumomab Y-90 ibritumomab tiuxetan
Number of patients 59 57
Median age of patients, years 50  60 
Patient population: percent low-grade or transformed 71 67
Dose range 25–75 cGy TBI 0.2–0.4 mCi/kg
Maximum tolerated dose 75 cGy TBI 0.4 mCi/kg
Dose limiting toxicity Haematologic pancytopenia Haematologic pancytopenia
Response rate, % 71 67
Median duration response, months 9 12 
Complete response rate, % 34 25
Fig. 1 Schema for anti-CD20 radiolabelled monoclonal antibody
radioimmunotherapy for CD20 positive B-cell lymphoma
Imaging/Biodistribution dose
D a y 01 2345678 9
Radionuclide scans: I-131 tositumomab
rituximab given with Y-90 ibritumomab tiuxetan; tositumomab given with I-131 tositumomab
Y-90 ibritumomab tiuxetan
Therapeutic dose
rituximab (250 mg/m2) or
tositumomab 450 mg
rituximab (250 mg/m2) or
tositumomab 450 mg
5mCi
111In ibritumomab tiuxetan or
131 I tositumomab
90Y-ibritumomab
tiuxetan (0.4 mCi/kg*) or
75 eGy TBI with 131I tositumomaband rituximab. Response rates were about 80% in patients
with follicular lymphoma [33–35], 70% in patients consid-
ered “resistant” to chemotherapy [35, 36] and 40% in trans-
formed lymphomas [37, 38]. For purposes of these trials,
chemotherapy resistance was defined as either no response
to the regimen, or a response that lasted less than 6 months.
Expanded access trials conducted with these products have
yielded similar results in larger populations of patients [39].
Table 4 summarises randomised trials that compared
the radiolabelled anti-CD20 antibodies to unlabelled tosi-
tumomab or rituximab in patients with low-grade lym-
phomas, mostly follicular, who had not previously been
treated with a monoclonal antibody. The response rates
and complete response rates were much higher for the
radiolabelled antibodies [35, 40]. The response rates
observed for rituximab in the Zevalin vs. rituximab trial
were similar to those reported in the pivotal trial of ritux-
imab as a single agent in patients with recurrent low-grade
lymphomas [4]. Based on trials of planned “maintenance”
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rituximab in low-grade lymphoma [7, 8], it is likely that
the duration of response in the radioimmunotherapy arm
would have been much longer if an equivalent amount of
rituximab had been given in that arm as in the control arm.
In the I-131 tositumomab trial, the response rate was 68%
among 19 patients who subsequently received the radiola-
belled antibody after initial randomisation and therapy
with unlabelled tositumomab; only three of these patients
had responded to tositumomab [40].
Table 5 summarises trials with the anti-CD20 antibod-
ies that were conducted in patients with CD20-positive
follicular lymphoma who had tumours that were consid-
ered “refractory” to rituximab [41, 42]. For purposes of
these trials, “refractory” was defined as lack of an objec-
tive tumour regression in response to rituximab, or disease
progression despite rituximab therapy (true refractori-
ness), or an objective response that lasted less than 6
months. In the I-131 tositumomab trial [42], five patients
were enrolled who had experienced a response of greater
R.O. Dillman: Radioimmunotherapy of B-cell lymphoma
Table 3 Clinical activity of radiolabelled anti-CD20 monoclonal antibodies in relapsed low-grade lymphomas [33–38]
I-131 tositumomab Y-90 ibritumomab tiuxetan
Follicular
Number of patients 185 73
Response rate, % 81 80
Median duration response, months 11  14 
Complete response rate, % 38 30
Transformed
Number of patients 71 15
Response rate, % 39 53
Complete response rate, % 25 –
Chemo-resistant
Number of patients 60 33
Response rate, % 65 73
Median duration response, months 6.5 –
Complete response rate, % 20 –
Table 4 Randomised trials of radiolabelled anti-CD20 monoclonal antibodies compared to unlabelled antibody in patients with recurrent
low-grade lymphoma including small lymphocytic, follicular and transformed low-grade lymphoma, who had not received monoclonal
antibody treatment in the past [35, 40]
I-131 tositumomab Y-90 ibritumomab tiuxetan
Number of patients 78 143
Median age of patients, years 56 58
Median number prior therapies 2 2
Percent chemo-resistant 23 48
Control therapy 450 mg tositumomab×2 250 mg/m2 rituximab×2
Dose limiting toxicity Haematologic pancytopenia Haematologic pancytopenia
Response rate 55% vs. 19% P=0.002 80% vs. 56% P=0.002
Median duration response NR vs. 28 months nsd 15.4 vs. 13.8 months nsd
Complete response rate 33% vs. 8% P=0.012 30% vs. 16% P=0.04
NR, not reached; nsd, not statistically significantthan 6 months, but the analysis was performed on all 40
patients as a group of patients who had progressed after
rituximab, 24 of whom actually progressed during ritux-
imab therapy, 11 who had a response to rituximab that last-
ed less than 6 months, and the five who had responded to
rituximab for more than 6 months. Because of the differ-
ences in patient populations one must be careful in trying
to draw conclusions regarding the comparable activity of
the two products in this setting. For instance, higher pro-
portions of patients in the Y-90 ibritumomab tiuxetan trial
had rituximab-refractory disease, and/or bulky disease
greater than 7 cm in diameter [41]. Response rates were
high in both trials, but the complete response rates were
lower and duration of response shorter in the Zevalin
patients than in other trials of this product, while the com-
plete response rate and duration of response with Bexxar
were similar to what had been seen in other trials. This
raises the issue of whether rituximab resistance or refrac-
toriness might be associated with changes in the CD20
structure that results in decreased affinity or avidity for the
radiolabelled ibritumomab, which binds exactly like ritux-
imab. Tositumomab binds to CD20 via different epitopes;
so it is possible that in the setting of rituximab resistance,
it might have more favourable binding characteristics than
ibritumomab which could be associated with better reten-
tion of the isotope at the tumour site.
Recent treatment with rituximab prior to radioim-
munotherapy with anti-CD20 radiolabelled antibodies
may alter the prevalence of available CD20 binding sites.
Under these circumstances, the 400–500 mg of unlabelled
antibody tositumomab or rituximab may be more than is
needed for optimal pharmacokinetics and biodistribution
of the radiolabelled antibodies, and may occupy most or
all of the CD20 sites so that there is limited opportunity for
the radiolabelled antibody to bind. In such situations most
of the radioimmunotherapy effect might result from non-
specific TBI rather than tumour-specific binding. In the
“rituximab-refractory” trial with Zevalin, patients who had
detectable levels of rituximab in their serum had a
response rate of 66%, while those who did not have mea-
surable residual rituximab had a response rate of 93%
(P=0.078) [41]. The presence of CD20-positive cells may
be a better indicator of the appropriateness of standard
dosing with Zevalin. In the “rituximab-refractory” trial,
patients who had detectable CD20-positive cells in the cir-
culation had a response rate of 88% compared to only 47%
for patients who did not have CD20-positive B cells pre-
sent (P=0.003) [41]. This issue was not addressed in the I-
131 tositumomab trial of patients who had progressed after
previous rituximab therapy [42].
For all patients that were enrolled in the various regis-
tration trials that led to approval of these products (250 for
Bexxar, 211 for Zevalin), about 33% had a durable
response of greater than a year, and about 25% had com-
plete responses that lasted more than a year [43–45]. The
median time to progression for all responders was 2.4 years
in the Zevalin trials and 3.8 years in the Bexxar trials. The
median time to progression for the durable complete
responders was 2.6 years in the Zevalin, and not reached at
a median follow-up of 5.3 years in the Bexxar trials. Once
again it is possible that the apparent difference in duration
of response is due to prognostic differences in the patient
populations, or it is possible that the durability of response
in the Zevalin trials is being reduced because of key differ-
ences in the CD20 molecule in the subset of patients who
were enrolled in the “rituximab-refractory” trials.
Similar to what has been observed with cytotoxic
chemotherapy and/or rituximab, the activity of the radiola-
belled anti-CD20 antibodies is not as high in patients who
have bulkier disease and/or larger tumour burdens,
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Table 5 Phase II trials of radiolabelled anti-CD20 monoclonal antibodies in patients with follicular lymphoma that was considered “refrac-
tory” to rituximab (no objective response or response of less than 6 months duration following rituximab) [41] or had progressed after rit-
uximab therapy [42]
I-131 tositumomab Y-90 ibritumomab tiuxetan
Number of patients 40 54
Median age of patients, years 57  54 
Median number prior therapies 4 4
≥High-intermediate IPI score, % 21 19
Rituximab “refractory”, % 88 100
Percent with a tumour ≥5 cm, % 50 74
Percent with a tumour ≥7 cm, % 32 44
Bone marrow involved, % 32 32
Response rate, % 65 74
Median progression-free survival, months 10.4  6.8
Complete response rate, % 38 16
IPI, international prognostic index; LDH, lactate dehydrogenasealthough the extent of previous therapy may be an even
more important variable. Among 54 patients treated with
Zevalin, the response rate was 100% among 14 patients
whose largest tumour was less than 5 cm in diameter, and
65% among 40 patients whose largest tumour was greater
than 5 cm in diameter [46]. Similarly, among 117 patients
treated with Bexxar, the response rate was 71% (41% com-
plete response rate) among 63 patients whose largest
tumour was less than 5 cm in diameter, and 65% (21%
complete response rate) among 54 patients whose largest
tumour was greater than 5 cm in diameter [47].
Response rates tend to be higher and more durable if
patients have received little or no prior therapy for lym-
phoma. In 76 patients with previously untreated follicular
lymphoma, the response rate to I-131 tositumomab was
95% with 75% complete response rate and 60% with doc-
umented molecular complete remissions [48]. At a median
follow-up of greater than five years, the 5-year progres-
sion-free survival rate was 59%, and the median progres-
sion-free survival was projected to be 6.1 years. Seventy
percent of the 57 complete responders were still in remis-
sion four to eight years following therapy. Patients in this
trial had a median age of only 49 years, which is more than
a decade younger than the universal population of follicu-
lar lymphoma patients, and because of unintentional selec-
tion bias related to patients travelling to a single institution
for treatment, these patients actually had a lower tumour
burden and more slowly growing tumour than the typical
population of follicular lymphoma patients. Nevertheless,
the high response rate and durability of response following
a treatment that is delivered during a two-week period is
very impressive and as good as or better than one would
expect from treatment of such patients with chemotherapy
administered over five to six months. Areport describing a
limited experience with Zevalin appears to confirm the
high level of activity in patients with untreated disease
based on a 100% response rate among eight patients with
five attaining a complete response [49].
In an analysis of 236 lymphoma patients who received
Y-90 ibritumomab tiuxetan, the overall response rate and
complete response rates were higher among 63 patients
who had received only one chemotherapy regimen prior to
the radioimmunotherapy compared to 173 patients who
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had received two or more regimens. The response rates for
the respective populations were 86% vs. 72% (P=0.051)
and complete response rates were 49% vs. 28% (P=0.004)
[50]. Table 6 shows that response rates, complete response
rates, durability of responses and progression-free survival
following treatment with I-131 tositumomab are also high-
er in patients who have had less prior therapy [51]. The
1177 patients in this analysis also included some patients
who received I-131 tositumomab shortly following com-
pletion of six to eight months of standard chemotherapy as
part of a planned sequential treatment for previously
untreated patients.
Because of binding to CD20-positive cells in the bone
marrow and the non-specific radiation effects of circulating
radiolabelled antibodies, there was concern that some
patients who subsequently relapsed following anti-CD20
radioimmunotherapy might have insufficient bone marrow
reserve to allow safe delivery of additional cytotoxic thera-
py. Published reports suggest that subsequent cytotoxic
treatment is feasible at full doses, and associated with ben-
efit also for patients who previously received anti-CD20
radioimmunotherapy [52–56]. Retreatment with I-131 tosi-
tumomab at a dose of 75 cGy TBI in 32 patients who had
previously responded but subsequently relapsed was associ-
ated with a 56% response rate, 22% complete response rate,
median duration of response of 11 months, and toxicity that
was similar to that seen during an initial therapy [52].
Among 58 patients treated at Mayo Clinic, who had
relapsed after Zevalin therapy, subsequent chemotherapy
was associated with no more marrow toxicity than seen in
contemporary controls who had received similar
chemotherapy, but had not received radiolabelled antibodies
previously [53]. At the time of the report, eight patients had
gone on to receive high-dose chemotherapy with stem cell
rescue after successful autologous stem cell harvest. A larg-
er analysis of 153 patients who received treatment follow-
ing relapse after Zevalin therapy noted response rates of
80% for focal radiation therapy, 53% for chemotherapy and
58% for rituximab [54, 55]. Among 38 patients treated at
Cornell who had relapsed after Bexxar therapy, subsequent
chemotherapy was also safely given, and several patients
attained a tumour response, including nine who underwent
allogeneic or autologous stem cell transplant [56].
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Table 6 Correlation between efficacy and timing of I-131 tositumomab anti-CD20 radioimmunotherapy in relation to other treatments for
low-grade and transformed CD20 positive B-cell lymphoma
1st therapy 2nd therapy 3rd therapy 4th therapy
Number of patients 141 226 228 540
Response rate, % 95 73 58 46
Median response duration, months Not reached 35  16 12
Complete response rate, % 78 46 32 23
PFS >1 year, % 82 59 42 27
Modified from Gregory et al. [51]; PFS, progression free survivalSeveral studies in patients with newly diagnosed fol-
licular lymphoma have demonstrated the feasibility of
administering standard doses of anti-CD20 radioim-
munotherapy immediately following six to eight cycles of
standard chemotherapy. These trials have included CHOP
chemotherapy followed by Bexxar (n=102) [57], CVP
chemotherapy followed by Bexxar (n=30) [58], fludara-
bine followed by Bexxar (n=35) [59] and rituximab+CHOP
or rituximab+CVP followed by Zevalin (n=28) [60]. In all
of these studies, the addition of radioimmunotherapy was
not associated with more toxicity than has been seen in
other settings; and there was some increase in the response
rate. Only one of these trials involved giving radioim-
munotherapy following a combination of chemotherapy
and rituximab, which is the most popular treatment regi-
men for low-grade lymphoma [60]. There is an ongoing
trial that compares CHOP+rituximab to CHOP followed
by I-131 tositumomab.
Another issue is whether anti-CD20 radioimmunother-
apy can be safely administered to patients who relapse
after previous high-dose chemotherapy and autologous
stem cell rescue. Such patients were ineligible for the key
registration trials for these products. A limited experience
in eight patients who subsequently received Y-90 ibritu-
momab tiuxetan following relapse after an autologous
transplant suggested that it is feasible to treat such patients
with standard dose anti-CD20 radioimmunotherapy [61].
On the other hand, in a phase I dose escalation trial in 15
patients who had previously undergone high-dose
chemotherapy with stem cell rescue, it appeared that 2
mCi/kg was the maximum tolerated dose for the product in
the post-autologous transplant setting [62].
Radioimmunotherapy has been safely integrated into the
treatment of stem cell transplant patients as a replacement
for TBI, and has been explored in higher doses as a single
agent. Based on estimates of dosing to critical target organs,
early trials of high-dose anti-CD20 radioimmunotherapy
utilised 280–785 mCi of I-131-labelled anti-CD20 antibody
B1 [63–65]. There was a 79% complete response rate among
the first 29 relapsed lymphoma patients so treated, and a
42% progression-free survival rate at a median follow-up of
42 months [65]. Analysis has suggested a maximum tolerat-
ed dose of 25 Gy to the key target organs for I-131 tositu-
momab when it is combined with etoposide (60 mg/kg) and
cyclophosphamide (100 mg/kg) (EC) high-dose chemother-
apy in patients with relapsed lymphoma [66]. At two years of
follow-up, compared to a cohort of contemporary control
patients, outcomes were better for the patients who received
anti-CD20 radioimmunotherapy with their high-dose EC
chemotherapy rather than traditional external beam TBI:
68% vs. 53% progression-free survival, and 83% vs. 52%
overall survival [67]. Among follicular lymphoma patients,
27 who received radioimmunotherapy TBI with their
chemotherapy had better progression-free survival rates at 5
years, 48% vs. 29% (P=0.006), and better overall 5-year sur-
vival rates, 67% vs. 53% (P=0.002) compared to 98 relapsed
follicular lymphoma patients who received the same
chemotherapy with or without traditional external beam TBI
[68]. The Y-90 anti-CD20 radiolabelled antibody is also
being explored as a high-dose therapy, and/or in conjunction
with high-dose chemotherapy with stem cell rescue, with a
good safety profile and encouraging efficacy [69–71].
Outcomes for lymphoma patients treated with radiola-
belled anti-CD20 antibodies probably differ depending on
histology. Observations of patients with intermediate-grade
lymphoma, who were enrolled in phase I trials, suggested
that response rates were about half those seen in patients
with low-grade lymphoma [30, 31]. A recent report describ-
ing 104 patients with relapsed large B-cell lymphoma, who
were not considered to be candidates for a stem cell trans-
plant approach, seemed to confirm this with an objective
response rate of 44% after treatment with Zevalin [72].
However, the response rate was actually greater than 50%
among 76 patients who had received only chemotherapy,
compared to a response rate of only 19% among patients
who previously had been treated with chemotherapy plus rit-
uximab. Responses have also been observed in mantle cell
lymphoma with 10/12 patients responding to radiolabelled
anti-CD20 as initial treatment [73] and 5/15 in patients who
had relapsed or were refractory to prior therapy [74].
Patient selection for anti-CD20 radioimmunotherapy is
important to minimise patient risk [20]. Patients should have
adequate cell counts and marrow reserve, with limited
replacement of bone marrow with malignant CD20-positive
cells. Except for recent trials exploring lower radiation doses
from radiolabelled anti-CD20 antibodies, all studies have
been restricted to patients with less than 25% of the marrow
involved with lymphoma. As summarised in Fig. 2, the rates
of grade IV cytopenia associated with Zevalin therapy
became progressively worse as marrow involvement in-
creased from 0%–5% to 6%–20%, to 20%–25% [75].
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Fig. 2 Relationship between extent of bone marrow involvement
with lymphoma and grade III and IV haematotoxicity associated with
Y-90 ibritumomab tiuxetan treatment of low-grade and transformed
CD20-positive B-cell lymphoma. Modified from Witzig et al. [75]
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6-20% >20%Because of the marrow toxicity, there is also interest regard-
ing the activity of lower doses of radiolabelled anti-CD20
antibodies. In patients who were thrombocytopenic with
platelet counts between 100 000 and 149 000/ml, a 3 mCi/kg
dose of Y-90 ibritumomab tiuxetan resulted in an 83%
response rate in patients with relapsed follicular lymphoma
[76], which is the same response rate that was seen at 4
mCi/kg [35]. The durability of response at this lower dose
was also comparable to that seen in trials at the maximum
tolerated dose [77].
The toxicities associated with radiolabelled anti-CD20
may be characterised as: (1) acute, the infusion-related reac-
tion associated with the binding of antibody to circulating
CD20-positive cells and the removal of those cells; (2) sub-
acute, the pancytopenia associated with the binding of anti-
CD20 antibodies to cells in the bone marrow with the dam-
age to nearby progenitor cells and the effects of non-specif-
ic radiation as the radiolabelled antibodies pass through the
bone marrow vasculature; and (3) chronic, the risk of
myelodysplastic syndrome (MDS) and/or acute myeloge-
nous leukaemia (AML) because of sublethal radiation dam-
age to bone marrow stem cells. The infusion reaction prob-
lem is self-limited and is now familiar to medical oncolo-
gists and haematologists who are used to seeing such reac-
tions in association with rituximab [32]. The bone marrow
suppression is typically maximal in the second month after
treatment and usually resolves in the third month [75]. It has
been hypothesised that the 5-mm path length for the beta
emission for Y-90 may be more marrow suppressive than
the 1-mm path length for the I-131 beta emission, but the
rates of significant cytopenias have been similar in the trials
of the two products. In patients who have previously
received cytotoxic therapy, and then received radiolabelled
antibodies, the rates of MDS/AML are no higher than has
been seen in patients with treated lymphoma who have not
received radioimmunotherapy, but the median follow-up in
these reports has been relatively short [78, 79]. After a
median follow-up of more than five years, no episodes of
MDS/AML had been observed among the 76 follicular lym-
phoma patients who received Bexxar as initial therapy [48].
There is also a theoretical concern for long-term risk of
other malignancies because of low-dose radiation. A higher
rate of stomach cancer has been documented in patients who
received thyroid ablative doses of I-131 for hyperthy-
roidism, which could relate to the physiologic iodine pump
in gastric tissues [80]. Hypothyroidism has been document-
ed in about 20% of patients who have received Bexxar, and
is readily managed with thyroid replacement. Human anti-
mouse antibodies (HAMA) have been detected in about
1%–2% of patients receiving ibritumomab with rituximab,
as compared to a rate of about 10% among patients receiv-
ing tositumomab. The latter group is exposed to about ten
times more mouse protein during the respective therapies.
However, the proportion of patients experiencing HAMA
was more than 60% in the trial of Bexxar in previously
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untreated follicular lymphoma patients [48], presumably
because they had not had previous treatment with immuno-
suppressive cytotoxic therapies.
Conclusions
Anti-CD20 radiolabelled antibodies are highly effective
products for the treatment of B-cell lymphoma. In previous-
ly untreated low-grade lymphoma, response rates are as
high as for chemotherapy, but are achieved after only two
weeks of therapy as opposed to five to six months for cyto-
toxic chemotherapy using standard dose regimens.
Unfortunately, there is little data regarding the benefit of
these products in patients who have failed combination ther-
apy with chemotherapy and rituximab, and there is very lit-
tle data in patients who are truly refractory to rituximab as
opposed to being relatively resistant. Patient selection is
important to minimise toxicity and optimise efficacy. The
modality has been underutilised, probably because of the
coordination required between medical oncologists/haema-
tologists and nuclear medicine specialists or radiation
oncologists, and the excellent results that have been
achieved with chemotherapy plus rituximab in recent years.
A randomised trial comparing the anti-CD20 radiolabelled
antibodies has been proposed, but it is unclear whether it
can ever be completed. An important trial will be a compar-
ison in previously untreated follicular lymphoma patients,
of radioimmunotherapy plus rituximab vs. chemotherapy
plus rituximab, in terms of efficacy and quality of life.
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